Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Jun 30, 2022 10:27am
181 Views
Post# 34793629

Excerpt from a Florida Hospital story about Ifenprofil.

Excerpt from a Florida Hospital story about Ifenprofil."But there is hope. Westchester is among a few hospitals around the world studying a new drug. Dr. Jose Suarez: So were doing a trial with Algernon, a medication called Ifenprodil, which has been around since the 70s, and were starting to use it on COVID patients, and its a potent anti-inflammatory. Its hoped the drug will reduce the scarring of lung tissue which has led to so many long term problems. Right now, its only being used on critically ill patients, and Dr. Suarez says the results are looking good. Dr. Jose Suarez: These patients are not getting that scarring that we usually see with the COVID patients, and their reactions to the treatment is phenomenal. Dr. Suarez says 10 patients who have received the drug have recovered from COVID without the scarring, and he believes studies like this one provide hope for future COVID patients". Full Stop What we were told by the CEO is it was too expensive to retrieve the X-ray data for all the patients who participated in the study. We were left dangling with the IDEA that we were onto some miracle drug results. Results without the data to back it up. We ultimately know what happened, and to this day do not know if management ever got a look at any of those X-rays for 200+ patients. Just left it all on the table. Does that make any sense? Overhype Under Deliver. End of story.
<< Previous
Bullboard Posts
Next >>